Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Cash & Equivalents (2020 - 2026)

GeneDx Holdings has reported Cash & Equivalents over the past 7 years, most recently at $93.9 million for Q1 2026.

  • Quarterly Cash & Equivalents fell 5.8% to $93.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $93.9 million through Mar 2026, down 5.8% year-over-year, with the annual reading at $105.0 million for FY2025, 23.22% up from the prior year.
  • Cash & Equivalents was $93.9 million for Q1 2026 at GeneDx Holdings, down from $105.0 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $315.0 million in Q1 2022 and troughed at $56.1 million in Q2 2024.
  • The 5-year median for Cash & Equivalents is $99.7 million (2023), against an average of $130.1 million.
  • The largest YoY upside for Cash & Equivalents was 973.92% in 2022 against a maximum downside of 69.06% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $123.9 million in 2022, then dropped by 19.57% to $99.7 million in 2023, then dropped by 14.52% to $85.2 million in 2024, then increased by 23.22% to $105.0 million in 2025, then fell by 10.55% to $93.9 million in 2026.
  • Per Business Quant, the three most recent readings for WGS's Cash & Equivalents are $93.9 million (Q1 2026), $105.0 million (Q4 2025), and $96.0 million (Q3 2025).